1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation.
We have recently shown that solid-phase immobilization of anti-1F7 recognizing the 110-kDa CD26 Ag is comitogenic for human peripheral blood T cell activation via both the CD3 and CD2 pathways. We have also demonstrated that binding of anti-1F7 leads to the disappearance of CD26 surface expression, and this anti-1F7-induced modulation results in an increase in anti-CD3 or anti-CD2-mediated peripheral blood T cell activation. In this report, we extended these findings by examining the expression and functional relationship of 1F7 on the CD3 and CD2 pathways of activation of human thymocytes. We now demonstrated that most of the anti-1F7 reactivity is found on medullary thymocytes, the population of thymocytes expressing high level of CD3 (CD3H). We have also shown that binding of anti-1F7 can induce a decrease in CD26 surface expression, with no detectable effect on the surface expression of CD3 or CD2. Most importantly, we showed that solid-phase immobilization of anti-1F7 has a comitogenic effect on thymocyte activation induced by anti-CD3 but not anti-CD2. In addition, anti-1F7-induced modulation of CD26 results in an enhancement in CD3-mediated but not CD2-mediated human thymocyte activation. The observed functional effect of CD26 on the CD3/TCR pathway of activation is mainly restricted to mature thymocytes as distinguished by high surface expression of CD5, although CD26 is also functionally associated with the CD3/TCR pathway on cells expressing low level of CD5. Demonstrating that CD26 involvement in the regulation of human thymocyte activation is restricted mainly to the CD3 pathway, unlike its involvement with both the CD3 and CD2 pathways of mature peripheral blood T lymphocyte activation, our data hence suggested that CD26 may play a role in thymic differentiation and maturation via the differential engagement of the CD3 pathway.
Dang
N H
NH
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115.
Torimoto
Y
Y
Shimamura
K
K
Tanaka
T
T
Daley
J F
JF
Schlossman
S F
SF
Morimoto
C
C
D000911:Antibodies, Monoclonal / Q000276:immunology*; D016525:Antigenic Modulation; D015703:Antigens, CD / Q000032:analysis / Q000276:immunology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000737:chemistry / Q000276:immunology*; D018801:CD2 Antigens; D017252:CD3 Complex; D018956:CD5 Antigens; D002118:Calcium / Q000502:physiology; D018819:Dipeptidyl Peptidase 4; D015536:Down-Regulation; D005434:Flow Cytometry; D006801:Humans; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008970:Molecular Weight; D011948:Receptors, Antigen, T-Cell / Q000276:immunology* / Q000378:metabolism; D011971:Receptors, Immunologic / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D013950:Thymus Gland / Q000166:cytology / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D017252:CD3 Complex; D018956:CD5 Antigens; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D018819:Dipeptidyl Peptidase 4; D002118:Calcium